Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic Burkitt lymphoma in Malawi; an open-label, single-arm, phase 2 study (ISRCTN34303497)

Br J Haematol. 2014 Mar;164(6):888-90. doi: 10.1111/bjh.12681. Epub 2013 Nov 25.
No abstract available

Keywords: Burkitt lymphoma; bezafibrate; efficacy; medroxyprogesterone; toxicity.

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bezafibrate / administration & dosage
  • Burkitt Lymphoma / drug therapy*
  • Burkitt Lymphoma / epidemiology
  • Burkitt Lymphoma / pathology
  • Child
  • Child, Preschool
  • Drug Resistance, Neoplasm
  • Endemic Diseases
  • Female
  • Humans
  • Malawi / epidemiology
  • Male
  • Medroxyprogesterone Acetate / administration & dosage
  • Recurrence

Substances

  • Medroxyprogesterone Acetate
  • Bezafibrate

Associated data

  • ISRCTN/ISRCTN34303497